Akebia Therapeutics, Inc.
AKBA
$0.88
$0.033.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 18.69% | 54.73% | 92.30% | 65.42% | 9.79% |
| Total Depreciation and Amortization | -91.98% | -95.49% | -96.62% | -75.36% | -53.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.80% | 59.58% | 79.79% | 154.03% | 467.34% |
| Change in Net Operating Assets | 157.23% | 139.92% | 141.52% | 83.61% | 27.82% |
| Cash from Operations | 1,829.17% | 273.41% | 267.22% | 184.15% | 93.83% |
| Capital Expenditure | -770.27% | -556.86% | -781.82% | -619.35% | -410.34% |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -50,495.83% | -6,828.93% | -23,918.18% | -64.52% | 182.76% |
| Total Debt Issued | -100.00% | -100.00% | -77.78% | -77.78% | -77.78% |
| Total Debt Repaid | -1,169.20% | -420.96% | 88.61% | 98.98% | 98.98% |
| Issuance of Common Stock | -94.90% | -96.60% | 58.86% | 230.50% | 254.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,609.40% | -180.00% | 4.95% | 95.05% | 22.00% |
| Cash from Financing | -111.18% | -102.77% | 46.84% | 284.29% | 302.85% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -81.34% | -31.00% | 1,382.48% | 1,160.93% | 792.51% |